Internal and Emergency Medicine, Journal Year: 2023, Volume and Issue: 18(5), P. 1255 - 1258
Published: July 7, 2023
Language: Английский
Biomedicine & Pharmacotherapy, Journal Year: 2023, Volume and Issue: 167, P. 115464 - 115464
Published: Sept. 15, 2023
Luteolin is a flavonoid widely present in various traditional Chinese medicines. In recent years, luteolin has received more attention due to its impressive liver protective effect, such as metabolic associated fatty disease, hepatic fibrosis and hepatoma. This article summarizes the pharmacological effects, pharmacokinetic characteristics, toxicity of against diseases, provides prospect. The results indicate that improves lesions through mechanisms, including inhibiting inflammatory factors, reducing oxidative stress, regulating lipid balance, slowing down excessive aggregation extracellular matrix, inducing apoptosis autophagy cancer cells. Pharmacokinetics research manifested bioavailability relatively low. It worth noting appropriate modification, new delivery systems, derivatives can enhance bioavailability. Although many studies have shown minimal, strict experiments are still needed evaluate safety promote reasonable development. addition, this study also discussed clinical applications related luteolin, indicating it key component commonly used drugs practice. view excellent expected become potential drug for treatment diseases.
Language: Английский
Citations
42
International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(11), P. 5640 - 5640
Published: May 22, 2024
The epidemiological burden of liver steatosis associated with metabolic diseases is continuously growing worldwide and in all age classes. This condition generates possible progression damage (i.e., inflammation, fibrosis, cirrhosis, hepatocellular carcinoma) but also independently increases the risk cardio-metabolic cancer. In recent years, terminological evolution from “nonalcoholic fatty disease” (NAFLD) to “metabolic dysfunction-associated (MAFLD) and, finally, steatotic (MASLD) has been paralleled by increased knowledge mechanisms linking local hepatic) systemic pathogenic pathways. As a consequence, need for an appropriate classification individual phenotypes oriented investigation innovative therapeutic tools. Besides well-known role lifestyle change, number pharmacological approaches have explored, ranging antidiabetic drugs agonists acting on gut–liver axis at level (mainly farnesoid X receptor (FXR) agonists, PPAR thyroid hormone agonists), anti-fibrotic anti-inflammatory agents. intrinsically complex pathophysiological history MASLD makes selection single effective treatment major challenge, so far. this evolving scenario, cooperation between different stakeholders (including subjects risk, health professionals, pharmaceutical industries) could significantly improve management disease implementation primary secondary prevention measures. high healthcare search new, effective, safe pressing need, together accurate characterization phenotypes. Recent promising advances indicate that we may soon enter era precise personalized therapy MASLD/MASH.
Language: Английский
Citations
21
European Journal of Internal Medicine, Journal Year: 2023, Volume and Issue: 119, P. 13 - 30
Published: Oct. 4, 2023
Language: Английский
Citations
29
European Journal of Internal Medicine, Journal Year: 2024, Volume and Issue: 124, P. 35 - 39
Published: April 22, 2024
The medical term nonalcoholic fatty liver disease (NAFLD) was coined in 1986 for a condition that has since become the most prevalent disorder worldwide. In last 3 years, global professional community launched 2 consecutive efforts to purge NAFLD from dictionary and recommended new terms based on pathophysiology rather than distinction similar conditions featuring steatosis. A consensus by renowned clinical scholars primarily residing Asian-Pacific region introduced metabolic dysfunction-associated (MAFLD) as name replace 2020. 2023, nomenclature classification resulting steatotic (MASLD) developed large expert panel under auspices of leading societies Europe Americas. These marked rapid shifts have garnered attention many researchers clinicians across globe due multilevel impact frequent potentially progressive chronic both adult pediatric populations. proposed terminologies differ several ways but they more common differences. They capture key features associated with cardiometabolic risk factors significant all-cause liver-related mortality. framework MASLD incorporated innovative aspects MAFLD while conceptual disparities remain work progress, should focus insights into pathogenesis, outcome trajectories, prevention, treatment. Here, some these challenges are discussed facilitate this process.
Language: Английский
Citations
11
European Journal of Internal Medicine, Journal Year: 2024, Volume and Issue: 125, P. 57 - 66
Published: March 14, 2024
Language: Английский
Citations
10
Annals of Hepatology, Journal Year: 2023, Volume and Issue: 28(6), P. 101138 - 101138
Published: July 18, 2023
Non-alcoholic fatty liver disease (NAFLD) represents a global public health burden. Despite the increase in its prevalence, has not received sufficient attention compared to associated diseases such as diabetes mellitus and obesity. In 2020 it was proposed rename NAFLD metabolic dysfunction-associated (MAFLD) order recognize risk factors complex pathophysiological mechanisms with development. Furthermore, along implementation of diagnostic criteria, aim is address whole clinical spectrum disease, regardless BMI presence other hepatic comorbidities. As would be expected paradigm shift, differing viewpoints have emerged regarding benefits disadvantages renaming disease. The following review aims describe way MAFLD from historical, perspective highlight why approach follow.
Language: Английский
Citations
20
Reviews in Endocrine and Metabolic Disorders, Journal Year: 2023, Volume and Issue: 24(5), P. 767 - 773
Published: Aug. 4, 2023
In this thematic issue on phenotyping the obesities, prominent international experts offer an insightful and comprehensive collection of articles covering current knowledge in field. order to actually capture all polyhedral determinants diverse types obesity, granularity phenotypic information acquired must be expanded context a personalized approach. Whilst use precision medicine has been successfully implemented areas like cancer other diseases, health care providers are more reluctant embrace detailed guide diagnosis, treatment prevention obesity. Given its multiple complex layers, necessarily needs go beyond multi-omics approach incorporate spheres that conform reality people living with Potential barriers, difficulties, roadblocks opportunities together their interaction syndemic analyzed. Plausible lacunae also highlighted addition pointing need redefining new conceptual frameworks. Therefore, extraordinary state-ofthe-art reviews provides useful both experienced clinicians trainees as well academics steer clinical practice research management obesity irrespective setting or career stage.
Language: Английский
Citations
19
Microorganisms, Journal Year: 2024, Volume and Issue: 12(11), P. 2333 - 2333
Published: Nov. 15, 2024
The human gut is a complex ecosystem that supports billions of living species, including bacteria, viruses, archaea, phages, fungi, and unicellular eukaryotes. Bacteria give genes enzymes for microbial host-produced compounds, establishing symbiotic link between the external environment host at both systemic levels. microbiome, which primarily made up commensal critical maintaining healthy host's immune system, aiding digestion, synthesizing essential nutrients, protecting against pathogenic as well influencing endocrine, neural, humoral, immunological functions metabolic pathways. Qualitative, quantitative, and/or topographic shifts can alter resulting in dysbiosis dysfunction, contribute to variety noncommunicable illnesses, hypertension, cardiovascular disease, obesity, diabetes, inflammatory bowel cancer, irritable syndrome. While most evidence date observational does not establish direct causation, ongoing clinical trials advanced genomic techniques are steadily enhancing our understanding these intricate interactions. This review will explore key aspects relationship microbiota, eubiosis, health highlighting emerging strategies microbiome engineering potential therapeutic approaches various conditions.
Language: Английский
Citations
6
Current Hepatology Reports, Journal Year: 2023, Volume and Issue: 22(4), P. 221 - 227
Published: Oct. 26, 2023
Language: Английский
Citations
11
Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)
Published: Feb. 6, 2025
Metabolic Associated Fatty Liver Disease (MAFLD) is becoming a major global health concern due to its links with obesity, insulin resistance, and cardiovascular risk. This randomized clinical trial assessed the effects of combining time-restricted feeding (TRF; 16/8) Lacto-Ovo-Vegetarian (LOV) diet on various factors in overweight obese patients MAFLD. Forty-six participants were randomly assigned either intervention group (TRF LOV diet) or control group, 21 completing 12-week study each group. The showed significant reductions weight (-8.07 ± 4.31 kg), BMI (-2.70 1.32 kg/m2), waist circumference (-8.00 4.06 cm), as well ALT (-17.14 14.33 U/L), GGT (-21.09 24.06 Index (-26.90 15.81), levels (-3.89 4.69 mU/L), TNF-α (-11.85 12.52 pg/mL) compared (all P < 0.05). Lipid profiles also improved reduction triglycerides (-46.85 54.55 mg/dL) an increase HDL-C (3.91 5.07 (P These findings imply that TRF combined enhances metabolic markers, liver health, loss, thus potentially offering practical dietary approach for managing Further long-term studies are necessary validate these results investigate their applications.
Language: Английский
Citations
0